Pfizer CFO Dave Denton to exit

Pharma powerhouse names Cecile Guegan interim finance chief

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Viyash Scientific to acquire Italy’s BioForLife for Rs. 188 crore

The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe

HAB Pharma targets Rs. 3,000 crore revenue by 2030

Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions

Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350

DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability

Glenmark posts strong FY26 results with 27.5% revenue jump

WACKER launches contract research services to accelerate next-gen RNA & DNA therapies

The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments